3,995 Shares in AbbVie Inc. $ABBV Acquired by Evanson Financial LLC

Evanson Financial LLC acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV) in the second quarter, HoldingsChannel reports. The firm acquired 3,995 shares of the company’s stock, valued at approximately $1,005,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Litman Gregory Wealth Management LLC bought a new stake in AbbVie during the 4th quarter valued at about $28,000. Imprint Wealth LLC grew its stake in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after acquiring an additional 45 shares in the last quarter. Legacy Wealth Managment LLC ID grew its stake in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares in the last quarter. IFC & Insurance Marketing Inc. purchased a new position in shares of AbbVie during the fourth quarter worth approximately $31,000. Finally, WestEnd Advisors LLC increased its position in shares of AbbVie by 160.4% during the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on ABBV shares. Canaccord Genuity Group boosted their price target on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a report on Monday. Evercore set a $235.00 target price on AbbVie in a research report on Friday, May 15th. Wells Fargo & Company upped their target price on AbbVie from $260.00 to $295.00 and gave the stock an “overweight” rating in a report on Friday, July 10th. JPMorgan Chase & Co. increased their price target on AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Finally, DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $275.70.

AbbVie Stock Up 0.8%

Shares of ABBV stock opened at $245.82 on Friday. The firm has a market cap of $434.31 billion, a price-to-earnings ratio of 69.44, a PEG ratio of 0.81 and a beta of 0.30. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The company’s 50 day moving average is $241.96 and its 200 day moving average is $224.96.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts anticipate that AbbVie Inc. will post 14.06 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s payout ratio is 195.48%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.